Carbidopa monohydrate

244.24

244.105927

MNX7R8C5VO

C47431

2928000090

117 Ų

1.42 g/cm3

528.7°C at 760 mmHg

273.5ºC

Oral-rat LD50: 4810 mg/kg; Oral-Mouse LD50: 1750 mg/kg

Thermal decomposition to emit toxic nitrogen oxide fumes

IRRITANT

NONH for all modes of transport

3

MW5300000

The warehouse is low-temperature, ventilated and dry

P305 + P351 + P338

H319

|Warning|H302 (52.22%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P273, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 90 companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

moderately toxic

The combination of levodopa and carbidopa has been reported to cause serum aminotransferase elevations in up to 9% of patients, but these abnormalities are usually mild, asymptomatic and self-limiting. In rare instances, the aminotransferase elevations rise above 5 to 10 times the ULN and require discontinuation or dose adjustment. In addition, levodopa has been implicated in a small number of cases of clinically apparent, acute liver injury, but the clinical characteristics and typical pattern of enzyme elevations have not been characterized. There have been no published case reports of clinically apparent liver injury convincingly attributed to levodopa. In view of the long term and wide scale use of levodopa in Parkinson disease, clinically apparent liver injury with jaundice must be exceedingly rare.

Levodopa (L-Dopa) is an amino acid precursor of dopamine and is the most effective and commonly used drug in the treatment of Parkinson disease. Levodopa is usually combined with carbidopa, which is an inhibitor of L-amino acid decarboxylase, the plasma enzyme that metabolizes levodopa peripherally. Treatment with the combination of levodopa and carbidopa has been associated with mild and transient increases in serum enzymes in a proportion of patients and with very rare instances of clinically apparent acute liver injury.

Parkinson Disease Agents

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)|Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)|Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism. (See all compounds classified as Aromatic Amino Acid Decarboxylase Inhibitors.)

Carbidopa

Human Drugs -> EU pediatric investigation plans